Editorial
Vinicius Cavalheri
Comorbidades em pacientes com câncer de pulmão elegíveis para resecção cirúrgica: o impacto da hipertensão arterial sistêmica
Referências
1. World Health Organization. World Cancer Report 2014 WHO. Geneva. 2014.
2. Australian Institute of Health and Welfare. Cancer in Australia: an overview 2014. Cancer series No 90. Cat. no. CAN 88. Canberra: AIHW; 2014.
3. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e166S-e190S.
4. Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W, Batura-Gabryel H. Comorbidities with non-small cell lung cancer: Is there an interdisciplinary consensus needed to qualify patients for surgical treatment? Ann Thorac Med. 2018 Apr-Jun;13(2):101-7.
5. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Moller H. The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur J Cancer. 2012 Dec;48(18):3386-95.
6. Irie M, Nakanishi R, Yasuda M, Fujino Y, Hamada K, Hyodo M. Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer. Eur Respir J. 2016 Aug;48(2):495-503.
7. Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017 Jun;6:CD012020.